Available data insufficiently characterize the relative benefits of
various treatments for clinically localized prostate cancer, and all
therapies cause some harms.
http://www.annals.org/cgi/content/fu...0209v1#R5-2321
Last year, 218,000 men were diagnosed with prostate cancer, but nobody
can tell them what type of treatment is most likely to save their life.
Those are the findings of a troubling new report from the Agency for
Healthcare Research and Quality, which analyzed hundreds of studies in
an effort to advise men about the best treatments for prostate cancer.
The report compared the effectiveness and risks of eight prostate cancer
treatments, ranging from prostate removal to radioactive implants to no
treatment at all. None of the studies provided definitive answers.
Surprisingly, no treatment emerged as superior to doing nothing at all.
.... Prostate cancer is typically a slow-growing cancer, and many men can
live with it for years, often dying of another cause. But some men have
aggressive prostate cancers, and last year 27,050 men died from the
disease. The lifetime risk of being diagnosed with prostate cancer has
nearly doubled to 20 percent since the late 1980s, due mostly to
expanded use of the prostate-specific antigen, or P.S.A., blood test.
But the risk of dying of prostate cancer remains about 3 percent.
“Considerable overdetection and overtreatment may exist,'’ an agency
press release stated.
.... The study also evaluated research on “watchful waiting,'’ which
means monitoring the cancer and initiating treatment only if it appears
the disease is progressing.
http://well.blogs.nytimes.com/2008/0...ostate-cancer/